EL7.AI
StocksMedium•16 November 2026•
4 min read

European Recommendation for Povofortay; Commission Decision Still Expected in 2026

Key Facts

1Incyte expected a European Commission decision on Povofortay in the fourth quarter of 2026.
2The STOP-HS1 and STOP-HS2 studies met the primary endpoint at week 12 at doses of 45 and 75 mg.
3Through week 54, HiSCR50 response reached 71.4%, HiSCR75 reached 57% and HiSCR100 reached 29%.
4Complete clearance of inflammatory lesions reached 16.1% to 20.2% at week 54.
5Incyte expected potential U.S. approval in the first quarter of 2027.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting Povofortay, or povorcitinib, authorization to treat hidradenitis suppurativa, but the European Commission had not yet issued its decision, according to an October disclosure by Incyte. The company said a Commission decision was expected in the fourth quarter of 2026, making the committee’s recommendation a regulatory step ahead of a final decision on marketing in Europe. The treatment therefore remains at the recommendation stage in Europe, rather than having final approval. The development is based on data from a clinical program that included two Phase 3 studies, which showed treatment responses at different time points. The company also presented follow-up results through week 54, adding a picture of response durability and side-effect rates during the follow-up period.

Incyte said the CHMP issued its positive opinion in September 2026, recommending approval of Povofortay for hidradenitis suppurativa. In its disclosure, the company said: "We expect a regulatory decision from the European Commission in the fourth quarter of 2026." This timing sets out the next stage of the European process, with the Commission’s final decision still pending, according to the company. A recommendation differs from the granting of marketing authorization itself; the European Medicines Agency said the summary of product characteristics is published after the Commission grants the authorization. The therapeutic benefit cited by the agency is a reduction in skin lesions and pain compared with placebo among patients previously treated with tumor necrosis factor inhibitors, a more specific description than saying the assessments generally demonstrated efficacy.

In the two pivotal trials, STOP-HS1 and STOP-HS2, the treatment met the primary endpoint of HiSCR50 versus placebo at week 12 at doses of 45 and 75 mg, according to Incyte’s statement on the Phase 3 data. The measure assesses clinical response in hidradenitis suppurativa, while the extended follow-up results showed responses at more stringent thresholds. Through week 54, the share of participants achieving HiSCR50 reached 71.4%, while the rate reached as high as 57% for HiSCR75 and 29% for HiSCR100 across the two studies. The company said "clinically meaningful and sustained responses were observed across all cohorts in both studies" through week 54. It also pointed to improved responses at the higher thresholds, without presenting the figures cited here as a direct comparison with the placebo group over that extended period.

For clearance of inflammatory lesions, the company said 16.1% to 20.2% of patients achieved complete clearance, under the ANdT=0 criterion, at week 54. Incyte said: "Complete clearance of inflammatory lesions was achieved in 16.1% to 20.2% of patients at week 54." This measure captures a different outcome from the HiSCR50, HiSCR75 and HiSCR100 measures, as it concerns skin free of inflammatory lesions under the stated criterion. Alongside efficacy, the company reported safety data for the same follow-up period, saying the rate of serious adverse events ranged from 3.7% to 6.4% and was similar between the two studies. Adverse events leading to treatment discontinuation ranged from 6.1% to 9.4%, which the company also described as low and similar across doses and studies.

The drug’s regulatory path also extends to the United States, where Incyte said the Food and Drug Administration accepted its new drug application for patients with moderate to severe hidradenitis suppurativa in the first quarter of 2026. The company added that it expected potential U.S. approval in the first quarter of 2027. That would put a potential U.S. decision after the timing set by the company for a European Commission decision in the fourth quarter of 2026, with each process subject to its own regulatory decision. Incyte had linked its European outlook to a Commission decision following the positive CHMP opinion in September. According to the company’s disclosure, the next European step remains the Commission’s expected decision during the fourth quarter of 2026.

Open on chart